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Background: The roots of Panax ginseng contain noble tetracyclic triterpenoid saponins derived from
dammarenediol-II. Dammarene-type ginsenosides are classiﬁed into the protopanaxadiol (PPD) and
protopanaxatriol (PPT) groups based on their triterpene aglycone structures. Two cytochrome P450 (CYP)
genes (CYP716A47 and CYP716A53v2) are critical for the production of PPD and PPT aglycones, respec-
tively. CYP716A53v2 is a protopanaxadiol 6-hydroxylase that catalyzes PPT production from PPD in
P. ginseng.
Methods: We constructed transgenic P. ginseng lines overexpressing or silencing (via RNA interference)
the CYP716A53v2 gene and analyzed changes in their ginsenoside proﬁles.
Result: Overexpression of CYP716A53v2 led to increased accumulation of CYP716A53v2 mRNA in all
transgenic roots compared to nontransgenic roots. Conversely, silencing of CYP716A53v2 mRNA in RNAi
transgenic roots resulted in reduced CYP716A53v2 transcription. HPLC analysis revealed that transgenic
roots overexpressing CYP716A53v2 contained higher levels of PPT-group ginsenosides (Rg1, Re, and Rf)
but lower levels of PPD-group ginsenosides (Rb1, Rc, Rb2, and Rd). By contrast, RNAi transgenic roots
contained lower levels of PPT-group compounds and higher levels of PPD-group compounds.
Conclusion: The production of PPD- and PPT-group ginsenosides can be altered by changing the
expression of CYP716A53v2 in transgenic P. ginseng. The biological activities of PPD-group ginsenosides
are known to differ from those of the PPT group. Thus, increasing or decreasing the levels of PPT-group
ginsenosides in transgenic P. ginseng may yield new medicinal uses for transgenic P. ginseng.
Copyright  2015, The Korean Society of Ginseng, Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Triterpenoid saponins are present in many higher plants and
exhibit a wide range of biological activities depending on their
structures. Certain triterpenoid saponins also have commercial
value and are exploited as drugs andmedicines [1e3], and saponins
may have natural roles in the defense against pathogens and pests
[4].
The roots of ginseng (Panax ginseng Meyer) contain pharmaco-
logically active components. It is generally believed that ginseno-
side saponins are the main compounds responsible for theurces, College of Forest Sciences, G
rk.
ht  2015, The Korean Society of G
c-nd/4.0/).pharmacological activities of P. ginseng [2,3]. Ginsenosides are
classiﬁed as protopanaxadiol (PPD) or protopanaxatriol (PPT) sa-
ponins based on their aglycone structures. PPD-group ginsenosides
have glycosidic bonds at the C-3 and C-20 hydroxyl groups, and the
major ginsenosides of this group include Ra1, Ra2, Rb1, Rc, Rd, and
Rg3. PPT-group ginsenosides have glycosidic bonds at the C-6 and
C-20 hydroxyl groups, and the major ginsenosides of this group
include Re, Rf, Rg1, Rg2, and Rh1.
The ﬁrst step in ginsenoside biosynthesis is the cyclization of
2,3-oxidosqualene to dammarenediol-II, which is catalyzed by
dammarenediol synthase of the oxidosqualene cyclase group [5].angwondaehak-gil 1, Kangwon National University, Chunchon 200-701, Republic of
inseng, Published by Elsevier Ltd. This is an open access article under the CC BY-NC-
J Ginseng Res 2016;40:47e5448Dammarenediol-II is hydroxylated by two cytochrome P450 en-
zymes (CYP716A47 and CYP71653v2) to produce PPDs and PPTs
[6,7]. These compounds are subsequently glycosylated by glyco-
syltransferase (Fig. 1). The CYP716A47 enzyme in P. ginseng cata-
lyzes the hydroxylation of dammarenediol-II at the C-12 position to
yield PPD, which is further hydroxylated at its C-6 position by
CYP71653v2 to yield PPT.
PPD-group ginsenosides have biological activities that are
opposite of those in the PPT group [8,9]. For example, Rg1 (PPT
group) stimulates the central nervous system, whereas Rb1 (PPD
group) suppresses the activity of the central nervous system [8,9].
Because the two CYP genes (CYP716A47 and CYP71653v2) are
necessary for producing PPD and PPT aglycones, respectively, we
postulated that modifying the expression of these genes in
P. ginseng could alter the composition of ginsenosides. Transgenic
ginseng with altered ginsenoside proﬁles could be used for newFig. 1. Biosynthetic pathway for ginsenosides in Panax ginseng. Squalene epoxidase
converts squalene to 2,3-oxidosqualene, which is then converted to a triterpene
aglycone (dammarenediol-II) by dammarenediol synthase. Dammarenediol-II un-
dergoes oxidation and glycosylation and is ﬁnally converted to protopanaxadiol (PPD)-
and protopanaxatriol (PPT)-group ginsenosides.medicinal applications requiring precise tuning of pharmacolog-
ical activity. In this study, we constructed two transgenic
P. ginseng lines, with overexpression or silencing [RNA interfer-
ence (RNAi)] of CYP716A53v2, and we analyzed the changes in
their PPD and PPT ginsenoside levels. We found that the pro-
duction of PPT-group ginsenosides was altered by both the
overexpression and RNAi-based silencing of the CYP716A53v2
gene.2. Materials and methods
2.1. Overexpression and RNAi silencing vector construction
The ORF (open reading frame) region of the CYP716A53v2
sequence was cloned into the pCR 8.0 vector (Invitrogen Life Tech-
nologies, Carlsbad, CA, USA) and then transferred to the destination
vector pH2WG to yield the CYP716A53v2 overexpression vector. To
construct the CYP716A53v2-RNAi vector, two primers including
gateway adapters (Invitrogen Life Technologies) were designed to
amplify the region from 1,259 bp to 1,498 bp in CYP716A53v2. The
ampliﬁed polymerase chain reaction (PCR) product was cloned into
the pSB1 vector and then transferred to the RNAi destination vector
pB7GWIWG2(II) (which contains the BAR gene that confers Basta
resistance to plant cells) in Escherichia coliDH5a, as described by the
manufacturer (Invitrogen Life Technologies). The construct was
sequenced and subsequently transformed into Agrobacterium
tumefaciens GV3101 cells harboring plasmid pMP90 using standard
molecular biology techniques.2.2. Construction of transgenic P. ginseng
The generation of transgenic P. ginseng was conducted as
described in our previous report [10]. Putative transgenic somatic
embryos for both CYP716A53v2 overexpression and CYP716A53v2-
RNAi were transferred to the selection medium, with additional
supplementation of 20mM GA3, to induce embryo germination. The
plantlets were maintained on 1/2-strength MS medium with 2%
sucrose.
Selection of transgenic root lines was performed as described by
Han et al [5]. As a nontransgenic control, adventitious roots were
induced from the in vitro maintained nontransformed plants that
were the original sources of the transgenic plants.2.3. Reverse transcription-PCR in transgenic roots
Total RNA was isolated from nontransgenic and transgenic
roots and reverse-transcribed using the ImProm-II Reverse Tran-
scription System (Promega, Madison, WI, USA). First-strand cDNA
was used as the template for the reverse transcription (RT)-PCR
analysis, which was performed as follows: 96C for 5 min; 30
cycles of 96C for 30 s, 60C for 30 s, 72C for 1 min; and a ﬁnal
extension at 72C for 10 min. b-Actin cDNA (primers 50-ATG GTC
AAG GCT GGA TTT GCA-30 and 50-CTC GAC CAG CTA AAT CAA GAC
G-30) was used as a control for RNA integrity and loading accu-
racy. The RT-PCR analyses were performed twice, and represen-
tative data are shown in the ﬁgures. The primers used for
ampliﬁcation were 50-ATG GAT CTC TTT ATC TCA TCT CAA-30 and
50-TTA AAG CGT ACA AGG TGA TAG ACG-30 for P. ginseng
CYP716A53v2, 50-GCG TGA CCT ATT GCA TCT CC-30 and 50-TTC TAC
ACA GCC ATC GGT CC-30 for the hygromycin phosphotransferase
gene (HPT), and 50-AGG ACA GAG CCA CAA ACA CC-30 and 50-ATG
CTT GTA TCC AGC TGC G-30 for the phosphinothricin acetyl
transferase gene (BAR).
S.-B. Park et al / Alteration of ginseng saponin 492.4. Quantitative PCR in transgenic roots
Quantitative PCR (qPCR) was performed using a Qiagen Rotor
Gene Q real-time PCR detector system (Qiagen, Hilden, Germany)
with SYBR Green PCR Kit (Qiagen, Valencia, CA, USA). The cycling
parameters for the qRT-PCR were as follows: 95C for 5 min, fol-
lowed by 35 cycles of 95C for 5 s and 60C for 10 s. The qRT-PCR
data shown are the average relative quantities  standard error
from at least three replicates. The relative expression level of each
gene was calculated using the DDCt method [11]. The P. ginseng b-
actin gene was used for normalization. The primers used for the
ampliﬁcation were as follows: 50-GGC CCC CTG CCA TAT CCA AAA
TCC-30 and 50-CAA AGT GCT GCC TCG TTG TCC G -30 for P. ginseng
CYP716A53v2; 50-ATG GTC AAG GCT GGA TTT GCA-30 and 50-GAG
CCT CAT ATC CAA CAT ATG C-30 for P. ginseng b-actin; 50-ATG CGG
AAA AGC AGA TCC CT-30 and 50-AAA TGC ATA CAG CAT CGC GG-30
for PgSS1; 50-AAG CTA GCG CTC TGC TCA TT-30 and 50-TGA TGA CGT
CCG TAC TTC CG-30 for PgSQE1; 50-ATA TAT CAG CGG AAC GAT TGA
CAC-30 and 50-ATT CAG CTA ATC CTT CTC CTA GCA A-30 for PgDDS;
50-GCA GCA GCA ATG GTG TTG TTT-30 and 50-TCG CCT ATC AAA GGC
CAA CC-30 for CYP716A47; 50-TTC GCA ATC ATC GAT TCG AGA AAA
A-30 and 50-AGA CTA CAC TGC CTG GAT TCT C-30 for PgPNX.
2.5. Ginsenoside analysis by HPLC
Extraction and analysis of ginsenosides was performed using
the method described by Han et al [6]. The HPLC separation wasA
B
C
Fig. 2. Expression of introduced genes in transgenic ginseng roots overexpressing CYP716
the control of the CaMV35S promoter. T35S, CaMV 35S terminator; HPT, hygromycin pho
(B) Conﬁrmation of transcription of the introduced genes (HPT and CYP716A53v2) by reverse t
(C) Transcription of CYP716A53v2 in nontransgenic (Nt) and transgenic lines (1e7) overexpress
the standard error obtained from three independent plants. Asterisks indicate signiﬁcant difperformed using a Cosmosil C18 column (5 mm, 4.6  250 mm;
Agilent, Santa Rosa, CA, USA). The time course measurements and
measurements of the ratios of water and acetonitrile were per-
formed according to the protocol reported by Han et al [6]. Each
ginsenoside was compared to authentic ginsenoside samples pur-
chased from ChromaDex, Inc. (Irvine, CA, USA).
3. Results
3.1. Overexpression and RNA interference of CYP716A53v2 in
transgenic P. ginseng
Transgenic ginseng plants overexpressing CYP716A53v2 were
generated using A. tumefaciens-mediated genetic transformation
(Fig. 2A). Transgenic root lines were induced and selected according
to the protocol by Han et al [5]. Seven transgenic overexpression
lines were ﬁnally selected for further analysis. The RT-PCR analysis
revealed clear transcription of the selection marker, hygromycin
phosphotransferase (HPT), in the overexpression lines (Fig. 2B). RT-
PCR showed higher transcript levels of CYP716A53v2 in roots of all
transgenic lines than in nontransgenic roots (Fig. 2C). Increases of>
2.5-foldwere achieved in all seven transgenic roots, as measured by
qPCR.
In transgenic ginseng plants for silencing (RNAi) CYP716A53v2
(Fig. 3A), expression of the selectionmarker gene, phosphinothricin
acetyl transferase (BAR), was clearly shown in all RNAi lines by RT-
PCR analysis (Fig. 3B). CYP716A53v2 transcript levels in all RNAiA53v2. (A) T-DNA region of the plasmid for CYP71653v2 gene overexpression under
sphotransferase gene; RB, right border of the T-DNA; LB, left border of the T-DNA.
ranscription-polymerase chain reaction (RT-PCR). b-Actinwas used as a loading control.
ing CYP716A53v2, based on quantitative PCR (qPCR). Data are shownasmean valueswith
ferences between nontransgenic and transgenic plants (Student t test, p  0.05).
Fig. 3. Expression of introduced genes in transgenic ginseng roots overexpressing CYP716A53v2-RNAi. (A) The T-DNA region of the plasmid for RNAi of the CYP71653v2 gene under
the control of the CaMV35S promoter. (B) Conﬁrmation of transcription of the introduced genes (BAR and CYP716A53v2) using genomic RT-PCR. b-Actin was used as a loading
control. (C) Transcription of CYP716A53v2 in Nt and CYP716A53v2-RNAi transgenic lines 1e7, based on qPCR. Asterisks indicate signiﬁcant differences between nontransgenic and
transgenic plants (Student t test, p  0.05). Data are shown as mean values with the standard error obtained from three independent plants. BAR, phosphinothricin acetyl
transferase; Nt, nontransgenic; qPCR, quantitative PCR; RNAi, RNA interference; RT-PCR, reverse transcription-polymerase chain reaction.
J Ginseng Res 2016;40:47e5450lines were clearly reduced compared to nontransgenic roots
(Fig. 3C). Asmeasured by qPCR, each of the CYP716A53v2-RNAi lines
showed a decrease of at least 75% in the level of the CYP716A53v2
transcript.
3.2. Altered ginsenoside proﬁles in transgenic P. ginseng
The HPLC chromatogram proﬁles revealed that PPT-group gin-
senosides (Rg1, Re, and Rf) were clearly reduced in the transgenic
RNAi line (line RNAi 3) (Fig. 4B) and were increased in the over-
expressing transgenic line (line over 7; Fig. 4C) compared with
those in the control (Fig. 4A). By contrast, PPD-group ginsenosides
(Rb1, Rb2, Rc, and Rd) were clearly enhanced in transgenic RNAi
roots (Fig. 4B) but reduced in overexpressing transgenic roots
(Fig. 4C).
The levels of PPT-group ginsenosides (Rg1, Re, and Rf) were
increased by at least 1.5-fold in all seven of the overexpression lines
relative to nontransgenic control roots (Table 1, Fig. 5A). However,
the levels of PPD-group ginsenosides (Rc, Rd, Rb1, and Rb2) were
reduced in overexpression lines compared with the controls. The
total ginsenoside levels in roots of the overexpression lines were
increased compared to those in the nontransgenic controls (Fig. 5A,
Table 1).
In transgenic RNAi lines, the levels of PPT-group ginsenosides
(Rg1, Re, and Rf) were clearly reduced compared with those in
nontransgenic roots (Table 2, Fig. 5B). In line 3, the PPT-group
ginsenosides were nearly absent. Interestingly, the total amount
of PPD-group ginsenosides (Rc, Rd, Rb1, and Rb2) was markedly
increased in all RNAi lines compared with the nontransgenic roots
(Fig. 5B). The total ginsenoside content was lowered in transgenic
RNAi lines comparedwith nontransgenic roots (Fig. 5B and Table 2).3.3. Expression of genes involved in ginsenoside biosynthesis in
transgenic lines
Squalene synthase is the ﬁrst enzymatic step leading from the
central isoprenoid pathway to ginsenoside biosynthesis [12]. It has
been reported that PgSS1 in P. ginseng is a regulatory enzyme not
only for phytosterol but also for triterpene biosynthesis [12].
Squalene epoxidase catalyzes the ﬁrst oxygenation step in ginse-
noside biosynthesis and is thought to be one of the rate-limiting
enzymes in this pathway. Han et al [13] reported that PgSQE1
and PgSQE2 are regulated via different mechanisms and that
PgSQE1 regulates ginsenoside biosynthesis but not phytosterol
biosynthesis. The production of the ginsenoside triterpene skel-
eton relies on the cyclization of 2,3-oxidosqualene to
dammarenediol-II catalyzed by dammarenediol synthase (PgDDS)
[5]. Han et al [6] reported that CYP716A47 is responsible for the
hydroxylation of dammarenediol-II at the C-12 position to yield
PPD. Cycloartenol synthase (PgPNX) in ginseng is involved in the
production of cycloartenol, which is the precursor for phytosterol
biosynthesis.
The transcription levels of genes related to ginsenoside
biosynthesis, such as PgSS1, PgSQE1, PgDDS, CYP716A47, and PgPNX,
were measured with qPCR in selected lines of transgenic ginseng
(overexpression and RNAi; Figs. 6, 7). Overexpression and RNA
interference of CYP716A53v2 did not affect the expression of up-
stream genes in the pathway (PgSS1, PgSQE1, PgDDS, and
CYP716A47); there was no clear change in mRNA accumulation
between the nontransgenic control and the transgenic roots
(Figs. 6, 7). Moreover, there was no difference in the accumulation
of PgPNXmRNA between transgenic roots and nontransgenic roots
(Figs. 6, 7).
Fig. 4. Ginsenoside chromatogram of extracts from nontransgenic and transgenic roots. (A) Ginsenoside chromatograms of extracts from nontransgenic roots. (B) Transgenic
CYP716A53v2-RNAi roots (line RNAi 3). (C) Transgenic P. ginseng roots overexpressing CYP716A53v2 (line over 7). (D) HPLC chromatogram of ginsenoside standards.
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4.1. Altered ginsenoside composition in transgenic P. ginseng
Transgenic ginseng plants were constructed to either over-
express or silence the CYP716A53v2 gene. RT-PCR and qPCR ana-
lyses revealed that all of the transgenic ginseng roots
overexpressing CYP716A53v2 showed increased CYP716A53v2
transcription. All of the CYP716A53v2-RNAi roots showed reduced
accumulation of CYP716A53v2 mRNA.Ginsenoside analysis by HPLC revealed that the transgenic
ginseng roots overexpressing CYP716A53v2 contained higher levels
of PPT-group ginsenosides (Rg1, Re, and Rf), whereas the
CYP716A53v2-RNAi roots contained lower levels. These results
indicate that the production of PPT-group ginsenosides is affected
by the engineered expression of CYP716A53v2. Overproduction of
PPTs in CYP716A53v2-overexpressing roots reduced the levels of
PPDs. Conversely, reduced PPT production in the CYP716A53v2-
RNAi roots stimulated the production of PPDs. These results indi-
cate that PPD and PPT production may be competing pathways that
Table 1
Ginsenoside concentrations in transgenic lines overexpressing CYP716A53v2
Line Ginsenoside concentration (mg/g dry weight) Total
PPT type PPD type
Rg1 Re Rf Rb1 Rc Rb2 Rd
Nt 2.73  0.28 1.03  0.18 0.11  0.13 1.56  0.19 0.19  0.17 0.51  0.02 0.17  0.11 6.30  0.62
Over 1 6.82  0.84 1.16  0.12 0.22  0.12 0.73  0.07 0.11  0.06 0.14  0.01 0.12  0.03 9.30  0.79
Over 2 6.42  0.52 1.22  0.19 0.21  0.22 0.64  0.05 0.07  0.01 0.16  0.03 0.17  0.02 8.89  0.68
Over 3 5.55  0.47 1.29  0.18 0.16  0.01 0.4  0.05 0.1  0.05 0.17  0.02 0.13  0.01 7.80  0.5
Over 4 6.78  0.61 1.35  0.13 0.23  0.02 0.65  0.03 0.09  0.01 0.16  0.03 0.13  0.01 9.39  0.55
Over 5 4.98  0.73 1.17  0.15 0.17  0.01 0.67  0.06 0.05  0.01 0.16  0.02 0.18  0.02 7.38  0.67
Over 6 8.24  0.43 1.58  0.17 0.29  0.03 0.56  0.03 0.09  0.01 0.14  0.01 0.11  0.01 11.01  0.48
Over 7 6.17  0.87 1.96  0.19 0.38  0.02 0.41  0.03 0.03  0.01 0.09  0.01 0.11  0.01 9.15  0.71
PPD, protopanaxadiol; PPT, protopanaxatriol
Fig. 5. HPLC analysis of ginsenosides in nontransgenic and transgenic ginseng roots.
(A) Ginsenoside contents in roots of transgenic lines (over 1 to 7) overexpressing
CYP716A53v2. (B) Ginsenoside contents in roots of CYP716A53v2-RNAi lines (RNAi 1 to
7). Data are shown as means  SE (n ¼ 3 each). Signiﬁcance was determined using
Student t test (* p  0.05; ** p  0.01) for independent means. Nt, nontransgenic roots;
SE, standard error.
Table 2
Ginsenoside concentration in RNAi transgenic lines silencing the CYP716A53v2 gene
Line Ginsenoside concentr
PPT type
Rg1 Re Rf Rb1
Nt 2.73  0.28 1.03  0.18 0.11  0.03 1.56  0.1
RNAi 1 0.45  0.03 0.09  0.01 d 2.62  0.1
RNAi 2 0.52  0.06 0.08  0.01 d 2.43  0.1
RNAi 3 0.07  0.01 d d 1.88  0.2
RNAi 4 0.28  0.02 d d 2.26  0.1
RNAi 5 0.35  0.03 0.08  0.01 d 2.67  0.3
RNAi 6 1.29  0.13 0.2  0.03 d 1.83  0.1
RNAi 7 1.06  0.11 0.1  0.01 d 2.53  0.2
Nt, nonstransgenic; PPD, protopanaxadiol; PPT, protopanaxatriol; RNAi, RNA interferenc
J Ginseng Res 2016;40:47e5452both depend on a common intermediate triterpene (dammar-
enediol-II).
Using qPCR, we investigated the expression of upstream genes
in the CYP716A53v2 overexpression and RNAi roots. Neither over-
expression nor RNAi affected the key upstream genes PgSS1,
PgSQE1, PgDDS, and CYP716A47, and there was no effect on the OSC
gene of the sterol pathway (PgPNX). These results strongly suggest
that altering CYP716A53v2 expression by using an engineered
promoter does not affect the upstream genes in the ginsenoside
biosynthesis pathway. The lower levels of PPD ginsenosides in
CYP716A53v2-overexpressing roots and the increase in PPD ginse-
nosides in CYP716A53v2-RNAi roots may result from complemen-
tary use of sapogenin (PPD and PPT) precursors in P. ginseng.
However, it is not clear why the total ginsenoside content differs
between the CYP716A53v2-overexpressing and CYP716A53v2-
silenced transgenic roots. To produce the ﬁnal PPD and PPT ginse-
nosides, various types of glycosyltransferases are required.
Recently, genes for a few glycosyltransferases involved in ginse-
noside biosynthesis have been identiﬁed [14]. It is likely that
changing the expression of CYP716A53v2 affects the downstream
genes (glycosyltransferases).
There are many reports of achieving increased ginsenoside
accumulation by elicitor or precursor treatment or by over-
expression of key ginsenoside biosynthesis enzymes in transgenic
P. ginseng [15]. Furuya et al [16] reported that treatment with
several intermediates and precursors involved in ginsenoside
biosynthesis, e.g., mevalonate or farnesol, was effective for
increasing ginsenoside production. Treatments with elicitors such
as yeast extract or methyl jasmonate also enhanced the ginsenoside
production [16,17]. Lee et al [12] found that squalene synthase
(PgSS1) increased the production of both phytosterols and ginse-
nosides. Overexpression of the PgSS1 gene in adventitious roots of
transgenic P. ginseng resulted in an increase in the production ofation (mg/g) Total
PPD type
Rc Rb2 Rd
9 0.19  0.17 0.51  0.02 0.17  0.11 6.30  0.51
2 0.32  0.02 0.55  0.03 0.27  0.03 4.30  0.2
7 0.26  0.01 0.46  0.02 0.26  0.03 4.01  0.17
1 0.34  0.02 0.48  0.04 0.28  0.02 3.05  0.18
9 0.44  0.03 1.2  0.13 0.23  0.02 4.41  0.27
1 0.53  0.04 0.86  0.07 0.24  0.01 4.73  0.27
9 0.35  0.02 0.56  0.04 0.24  0.03 4.47  0.25
2 0.26  0.01 0.39  0.04 0.26  0.03 4.60  0.24
e
Fig. 6. Quantitative polymerase chain reaction (qPCR) for genes upstream of ginsenoside biosynthesis in CYP716A53v2-overexpressing transgenic roots of Panax ginseng. Tran-
scription of PgSS1, PgSQE1, PgDDS, CYP716A47, and PgPNX in transgenic lines.
Fig. 7. Quantitative polymerase chain reaction (qPCR) for genes upstream of ginsenoside biosynthesis in CYP716A53v2-RNAi transgenic roots of Panax ginseng. Transcription of
PgSS1, PgSQE1, PgDDS, CYP716A47, and PgPNX in transgenic lines.
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J Ginseng Res 2016;40:47e5454phytosterols (b-sitosterol, stigmasterol, and campesterol) and gin-
senosides [12]. However, all of the above reports address the con-
trol of total ginsenoside biosynthesis. Our report is the ﬁrst to
describe ﬁne-tuning the biosynthesis of speciﬁc ginsenoside
groups.
The medicinal effects of these ginsenosides have been exten-
sively studied, and they are involved in the immune system, anti-
stress effects, antihyperglycemic activity, anti-inﬂammatory
activity, antioxidant activity, and anticancer effects [3,18]. In general,
the PPD-group ginsenosides have pharmaceutical activities that are
opposite those of the PPT group [8,9]. Therefore, transgenic ginseng
plants containing increased or reduced levels of PPT-group ginse-
nosides due to altered expression of CYP716A53v2 could be used as
new medicinal plants with speciﬁc pharmacological activities.
The physiological role of saponins in plants is not yet fully un-
derstood. Saponins may play important roles in plant defense. The
bitter taste of ginsenosides makes them antifeedants [19e23].
Various biological roles have been proposed for different saponins,
mostly involving allelopathic activity and defense against insects
and pathogens [22]. Ginsenosides have antimicrobial [24] and
antifungal activities in nature [25]. Ginsenosides also have antiviral
activities toward human viruses [26]. Lee et al [27] reported that
transgenic tobacco producing dammarenediol-II by overexpression
of the PgDDS gene confers resistance to tobacco mosaic virus by
inhibiting viral replication.
The fungus Cylindrocarpon destructans causes serious root rot
disease in ginseng-producing areas and is a main cause of ginseng
replant failure [28]. PPT- and PPD-group ginsenosides exhibit
different activities on C. destructans: PPT-group ginsenosides
inhibit its growth, whereas PPD-group ginsenosides signiﬁcantly
enhance its growth [25]. However, simply increasing the level of
total ginsenosides did not prevent the fungal pathogen from
invading the ginseng [25]. Thus, speciﬁcally increasing the levels of
PPT-group ginsenosides in transgenic ginseng by overexpressing
CYP716A53v2 may be necessary to provide defense against
C. destructans, thereby conferring resistance to root rot disease.
In conclusion, ginsenoside levels were successfully altered by
changing the expression of CYP716A53v2 in transgenic ginseng.
These transgenic P. ginseng plants can be used to produce new
genetically engineered cultivars with speciﬁc biological traits such
as changed medicinal values and defenses against ginseng patho-
gens and other microorganisms.Conﬂicts of interest
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